Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | $2.3 | $2.6 | $3.1 | $5.2 | $3.6 | $3.7 | $4.3 | $3.8 | $3.9 | $3.8 | $4.2 | $7.4 | $2.8 | $3.3 | $5.4 | $3.1 | $3.5 | $10.7 | $3.2 | $7.2 |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novartis AG's last 12-month EPS is $8.6, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novartis AG's EPS growth was 131.0%. The average annual EPS growth rates for Novartis AG have been 35.1% over the past three years, 11.0% over the past five years.
Over the last year, Novartis AG's EPS growth was 131.0%, which is higher than industry growth of (0.2%). It indicates that Novartis AG's EPS growth is Good.